Skip to content

Exploring Photon-Counting CT for Enhanced Target Delineation and Dose Accuracy in Personalized Radiotherapy - ANTHEM

Exploring Photon-Counting CT for Enhanced Target Delineation and Dose Accuracy in Personalized Radiotherapy - ANTHEM

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07098247
Acronym
RAD4/RT_ANTHEM
Enrollment
500
Registered
2025-08-01
Start date
2025-04-04
Completion date
2027-05-31
Last updated
2025-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Radiotherapy remains a cornerstone of oncology care, particularly for rare or orphan cancers and chronic oncologic and rare non oncologic conditions, where precision and individualized treatment planning are necessary. Advances in imaging technologies are crucial to overcome the challenges posed by these cases, especially in achieving accurate tumor delineation and dose delivery. Photon-counting CT (PCCT) represents a transformative step forward in imaging technology. Unlike conventional energy-integrating CT, PCCT offers a) superior spatial resolution, enabling clearer visualization of tumor margins and fine anatomical structures, b) enhanced tissue characterization, allowing better differentiation between tumor tissues and normal tissue; c) spectral imaging capabilities, facilitating improved dose calculations. These attributes are particularly advantageous in high-precision radiotherapy techniques, such as stereotactic body radiotherapy (SBRT) or proton therapy, where small errors in target delineation or dose delivery can significantly impact treatment outcomes. However, very limited data reporting the clinical use of PCCT for RT planning are available.

Interventions

None listed

Sponsors

Istituto Clinico Humanitas
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥18 years old patients * tumors located in challenging anatomical regions (brain, head and neck, liver, pancreas prostate), or Cardiac disease requiring RT by photon or proton at our Institution.

Exclusion criteria

\- 18 years old patients

Design outcomes

Primary

MeasureTime frameDescription
Improve RT target delineation accuracy and differentiation of organs-at-risk (OARs).day 1 (day of simulation TC)During the simulation, the investigator will evaluate the image quality obtained from photon-counting TC imaging compared to conventional imaging techniques, and assess how this improved imaging could enhance radiotherapy treatment planning. The data will be evaluated by indicative scores of imaging quality and treatement planning. minimum scale value is one and indicates a poor quality of the imaging - maximum scale value is five and indicates excellent image quality

Secondary

MeasureTime frameDescription
Enhanced dose calculation precision, particularly for proton therapyDay 1 (day of simulation TC)During the simulation, the investigator will evaluate the image quality obtained from photon-counting TC imaging compared to conventional imaging techniques, and assess how this improved imaging could enhance radiotherapy treatment planning. The data will be evaluated by indicative scores of imaging quality and treatement planning. minimum scale value is one and indicates a poor quality of the imaging - maximum scale value is five and indicates excellent image quality

Countries

Italy

Contacts

Primary ContactResearch study coordinator
laura.bonavita@humanitas.it+39 0282247026
Backup ContactResearch nurse
barbara.alt@humanitas.it+39 0282248513

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026